News articles about Opko Health (NASDAQ:OPK) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Opko Health earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.9126497515318 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
OPK has been the topic of several analyst reports. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $16.00 price target on shares of Opko Health in a research report on Monday, September 25th. Jefferies Group reaffirmed a “hold” rating and set a $6.50 price target (down from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, September 23rd. Finally, J P Morgan Chase & Co lowered shares of Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.97.
Opko Health (NASDAQ:OPK) traded down $0.07 during mid-day trading on Monday, hitting $5.14. 3,357,974 shares of the stock traded hands, compared to its average volume of 4,538,195. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66. Opko Health has a twelve month low of $4.50 and a twelve month high of $12.15.
Opko Health (NASDAQ:OPK) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. During the same period in the previous year, the company earned ($0.03) earnings per share. The company’s revenue was down 11.6% compared to the same quarter last year. sell-side analysts forecast that Opko Health will post -0.27 earnings per share for the current fiscal year.
In related news, CEO Phillip Md Et Al Frost purchased 80,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were purchased at an average cost of $6.01 per share, with a total value of $480,800.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $18,444,395.51. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Opko Health, Inc. purchased 655,738 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the purchase, the insider now directly owns 6,678,752 shares in the company, valued at approximately $20,370,193.60. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 1,052,238 shares of company stock worth $4,374,796. Corporate insiders own 40.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Opko Health (OPK) Receives Coverage Optimism Score of 0.10” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/04/opko-health-opk-receives-coverage-optimism-score-of-0-10.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.